H. Lundbeck A/S And Otsuka Pharmaceutical Co., Ltd. Initiate European Launch Of Abilify Maintena® (Aripiprazole), A Once-Monthly Formulation For The Treatment Of Schizophrenia

Published: Mar 17, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Europe Ltd. (Otsuka) today announced the launch of Abilify Maintena in Europe following approval by the European Commission in November 2013. Abilify Maintena is now available in a number of European countries and is progressing through the various Healthcare Authorities that provide access to patients. Denmark is the first European country where Abilify Maintena is fully reimbursed and accessible to people with schizophrenia, and more than ten markets are expected to launch by the end of 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news